Ikena Oncology (IKNA) Competitors $1.27 -0.03 (-2.31%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKNA vs. CRVS, YMAB, FHTX, PROK, CADL, CRGX, DSGN, ENGN, PLX, and OCGNShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Corvus Pharmaceuticals (CRVS), Y-mAbs Therapeutics (YMAB), Foghorn Therapeutics (FHTX), ProKidney (PROK), Candel Therapeutics (CADL), CARGO Therapeutics (CRGX), Design Therapeutics (DSGN), enGene (ENGN), Protalix BioTherapeutics (PLX), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Ikena Oncology vs. Corvus Pharmaceuticals Y-mAbs Therapeutics Foghorn Therapeutics ProKidney Candel Therapeutics CARGO Therapeutics Design Therapeutics enGene Protalix BioTherapeutics Ocugen Corvus Pharmaceuticals (NASDAQ:CRVS) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations. Which has more volatility & risk, CRVS or IKNA? Corvus Pharmaceuticals has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Do institutionals and insiders believe in CRVS or IKNA? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Ikena Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, CRVS or IKNA? Corvus Pharmaceuticals has higher earnings, but lower revenue than Ikena Oncology. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.97-3.70Ikena Oncology$659K93.00-$68.17M-$1.01-1.26 Does the media prefer CRVS or IKNA? In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Ikena Oncology. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 1 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.89 beat Corvus Pharmaceuticals' score of 0.73 indicating that Ikena Oncology is being referred to more favorably in the news media. Company Overall Sentiment Corvus Pharmaceuticals Positive Ikena Oncology Very Positive Do analysts rate CRVS or IKNA? Corvus Pharmaceuticals currently has a consensus price target of $15.67, suggesting a potential upside of 336.40%. Ikena Oncology has a consensus price target of $3.00, suggesting a potential upside of 136.22%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Corvus Pharmaceuticals is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer CRVS or IKNA? Corvus Pharmaceuticals received 263 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 62.08% of users gave Corvus Pharmaceuticals an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes29362.08% Underperform Votes17937.92% Ikena OncologyOutperform Votes3058.82% Underperform Votes2141.18% Is CRVS or IKNA more profitable? Ikena Oncology's return on equity of -36.88% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Ikena Oncology N/A -36.88%-33.08% SummaryCorvus Pharmaceuticals beats Ikena Oncology on 11 of the 17 factors compared between the two stocks. Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.29M$3.00B$5.57B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.0330.4222.4218.48Price / Sales93.00498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book0.363.206.774.25Net Income-$68.17M-$72.35M$3.22B$248.23M7 Day Performance4.96%3.57%3.26%3.29%1 Month Performance-3.79%0.17%0.02%2.42%1 Year Performance-3.79%-21.21%18.01%5.54% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology2.7431 of 5 stars$1.27-2.3%$3.00+136.2%-3.8%$62.74M$659,000.00-1.0370Positive NewsCRVSCorvus Pharmaceuticals2.344 of 5 stars$3.22-0.6%$15.67+386.5%+131.6%$219.40MN/A-3.4630Upcoming EarningsNews CoverageHigh Trading VolumeYMABY-mAbs Therapeutics3.7905 of 5 stars$4.82+2.8%$18.30+279.7%-72.1%$217.95M$87.69M-8.93150Upcoming EarningsShort Interest ↓News CoverageFHTXFoghorn Therapeutics3.0757 of 5 stars$3.90+2.6%$13.17+237.6%-23.1%$216.89M$22.60M-2.03120Upcoming EarningsAnalyst ForecastNews CoverageGap DownPROKProKidney2.4901 of 5 stars$0.73-7.3%$5.00+582.2%-57.1%$214.52M$76,000.00-1.333Positive NewsCADLCandel Therapeutics1.9825 of 5 stars$4.51-1.3%$21.00+365.6%-30.4%$213.03M$120,000.00-2.6160Gap DownCRGXCARGO Therapeutics2.1243 of 5 stars$4.60-0.9%$15.00+226.1%-76.1%$211.84MN/A-1.08116Positive NewsHigh Trading VolumeDSGNDesign Therapeutics1.8549 of 5 stars$3.59+2.6%$8.00+122.8%+38.1%$203.78MN/A-4.2240Upcoming EarningsPositive NewsENGNenGene3.3862 of 5 stars$3.99-0.3%$24.13+504.6%-74.0%$203.40MN/A-6.8831Analyst ForecastShort Interest ↑PLXProtalix BioTherapeutics2.6825 of 5 stars$2.55-2.3%$15.00+488.2%+169.3%$198.98M$53.40M-19.62200Positive NewsOCGNOcugen0.913 of 5 stars$0.68-0.3%$6.33+835.4%-43.4%$197.72M$4.06M-3.7680 Related Companies and Tools Related Companies CRVS Competitors YMAB Competitors FHTX Competitors PROK Competitors CADL Competitors CRGX Competitors DSGN Competitors ENGN Competitors PLX Competitors OCGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IKNA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
